HSA
VYGR icon

Hussman Strategic Advisors’s Voyager Therapeutics VYGR Stock Holding History

Hussman Strategic Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,500
Closed -$415K – 296
2024
Q2 		$415K Hold
52,500
– – 0.11% 195
2024
Q1 		$489K Hold
52,500
– – 0.11% 182
2023
Q4 		$443K Hold
52,500
– – 0.1% 189
2023
Q3 		$407K Buy
+52,500
New +$479K 0.08% 251

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hussman Strategic Advisors's VYGR Position: Q3 2024 in Review

Hussman Strategic Advisors sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 52,500 shares — an estimated $415K sold.

Hussman Strategic Advisors first reported a position in VYGR in Q3 2023 and held it in 4 quarters. The position peaked at $489K in Q1 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Hussman Strategic Advisors reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hussman Strategic Advisors sold 52,500 Voyager Therapeutics shares in Q3 2024, an estimated $415K.
  • Hussman Strategic Advisors first reported a position in Voyager Therapeutics in Q3 2023 and held it in 4 quarters.
  • Hussman Strategic Advisors's Voyager Therapeutics position peaked at $489K in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Hussman Strategic Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.